# HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

> **NCT00980239** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 115 (actual)

## Conditions studied

- Liver Cancer
- Advanced Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Bevacizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00980239
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2015-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00980239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00980239, "HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00980239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*